Fexofenadine is Safe in G6PD Deficiency
Fexofenadine can be safely used in patients with G6PD deficiency without special precautions. There is no evidence linking this second-generation antihistamine to hemolytic risk in G6PD-deficient individuals.
Evidence Supporting Safety
The FDA drug label for fexofenadine contains no warnings, precautions, or contraindications regarding G6PD deficiency 111. This absence of any G6PD-related safety concerns in the official prescribing information is significant, as medications with known hemolytic risk in G6PD deficiency typically carry explicit warnings.
The most comprehensive recent guideline on G6PD deficiency and medication use—the 2023 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline—systematically reviewed medications implicated as unsafe in G6PD deficiency 2. Antihistamines, including fexofenadine, are not classified as high, medium, or even low-risk medications for hemolysis in this authoritative guideline. This guideline specifically addresses medications that have been flagged by regulatory agencies or literature as potentially problematic, and fexofenadine's absence from all risk categories indicates it poses no recognized hemolytic concern.
Clinical Context
The medications that genuinely pose hemolytic risk in G6PD deficiency are well-established and include:
A 2024 real-world study of over 31,000 G6PD-deficient patients found that major hemolysis requiring hospitalization occurred in only 0.2% of patients, with 71.8% caused by fava beans and only 4.2% potentially medication-related 4. Antihistamines were not implicated in any hemolytic events.
Practical Recommendation
Use fexofenadine at standard doses (60 mg twice daily or 120-180 mg once daily for adults) without modification in G6PD-deficient patients 56. No additional monitoring beyond standard clinical assessment is required. The drug's excellent safety profile—comparable to placebo in clinical trials—extends to all patient populations studied 17.